Efficacy and safety of taxane plus anthracycline with or without cyclophosphamide in Chinese node-positive breast cancer patients: an open-label, randomized controlled trial
暂无分享,去创建一个
Q. Sun | Y. Zhong | Yidong Zhou | F. Mao | Yan Lin | J. Guan | Xin Huang | Yu Song | Ying Xu | Changjun Wang | Xing-ming Zhou
[1] A. D'Amico,et al. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.
[2] P. Liu,et al. Retrospective analysis of concurrent docetaxel and epirubicin neoadjuvant versus adjuvant chemotherapy , 2018, Medicine.
[3] Virginia G Kaklamani,et al. Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast Cancer , 2018, The New England journal of medicine.
[4] E. Warner,et al. Ovarian function after chemotherapy in young breast cancer survivors. , 2017, Current oncology.
[5] C. Criscitiello,et al. Maximizing the Clinical Benefit of Anthracyclines in Addition to Taxanes in the Adjuvant Treatment of Early Breast Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Jia Wei,et al. Feasible and efficient identification of neoantigens for personalized cancer immunotherapy in advanced refractory epithelial cancer patients. , 2017 .
[7] M. Hsieh,et al. Review of Advances in Uroprotective Agents for Cyclophosphamide- and Ifosfamide-induced Hemorrhagic Cystitis. , 2017, Urology.
[8] M. Somerfield,et al. Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] E. Starosławska,et al. Life quality of women with breast cancer after mastectomy or breast conserving therapy treated with adjuvant chemotherapy. , 2015, Annals of agricultural and environmental medicine : AAEM.
[10] Thomas J. Smith,et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Lori A. Eggert,et al. Optimisation of steroid prophylaxis schedules in breast cancer patients receiving docetaxel chemotherapy—a survey of health care providers and patients , 2015, Supportive Care in Cancer.
[12] D. Warr. Management of highly emetogenic chemotherapy , 2012, Current opinion in oncology.
[13] G. Nocea,et al. Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients’ quality of life , 2012, Supportive Care in Cancer.
[14] Marcus Schmidt,et al. Adjuvant chemotherapy in early breast cancer. , 2012, Minerva Ginecologica.
[15] M. Kris,et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] P. Goodwin,et al. Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001-2009). , 2011, Journal of the National Cancer Institute.
[17] E. Perez,et al. Changes to adjuvant systemic therapy in breast cancer: a decade in review. , 2010, Clinical breast cancer.
[18] M. Kris,et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] S. Grunberg. Obstacles to the implementation of antiemetic guidelines. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.
[20] Edith A Perez,et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] G. Sledge,et al. Taxane vs. taxane: is the duel at an end? A commentary on a phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study , 2008, Breast Cancer Research and Treatment.
[22] R. Gray,et al. Randomized clinical trial design for assessing noninferiority when superiority is expected. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] S. Ward,et al. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation. , 2007, Health technology assessment.
[24] S. Ward,et al. A systematic review and economic evaluation of statins for the prevention of coronary events. , 2007, Health technology assessment.
[25] G. Guyatt,et al. The clinical significance of quality of life assessments in oncology: a summary for clinicians , 2006, Supportive Care in Cancer.
[26] M. Milella,et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer , 2006, Cancer.
[27] M. Stockler,et al. Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. , 2004, The Lancet. Oncology.
[28] P. Ganz,et al. Health-related quality-of-life measurement in randomized clinical trials in breast cancer--taking stock. , 2003, Journal of the National Cancer Institute.
[29] D. Neuberg,et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] A. Riva,et al. Taxane/anthracycline combinations: setting a new standard in breast cancer? , 2001, The oncologist.
[31] A. Wolff,et al. Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: an Eastern Cooperative Oncology Group Study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] A. Jemal,et al. Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.
[33] E. Rutgers,et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[34] M. Koelemay,et al. Health and Quality of Life Outcomes , 2009 .
[35] Ali Montazeri,et al. Health-related quality of life in breast cancer patients: A bibliographic review of the literature from 1974 to 2007 , 2008, Journal of experimental & clinical cancer research : CR.
[36] C. Criscitiello,et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] J. Sparano,et al. Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.